Makers of organoids and cell models cheered the decision and said it will bolster the development of precision medicines, ...

Two family members with a germline ALK-mutant neuroblastoma both experienced complete response to ALK inhibitors in a case study.

The agency approved the treatment based on data from 57 patients with previously treated KRAS-mutant recurrent low-grade serous ovarian cancer.

If the agency approves its application, the firm will begin a Phase I clinical trial in c-MYC-driven cancers in 2026.

The funds will support a Phase I/II trial of its gene therapy candidate in an aggressive form of dilated cardiomyopathy due to LMNA gene mutations.

NEW YORK – Marengo Therapeutics said on Thursday it has started treating patients with certain types of breast cancer in a Phase Ib/II trial of its T-cell agonist, invikafusp alfa, plus Gilead's TROP2 ...

NEW YORK – Haya Therapeutics on Thursday said it has raised $65 million in a Series A funding round, which it will put toward accelerating development of its therapeutic pipeline, including its long ...

The firm will test LP-184 as a monotherapy and in combination with a PARP inhibitor in patients who have DNA damage repair gene mutations.

NEW YORK – Isarna Therapeutics said Wednesday that it will discuss with regulators the results of a Phase II trial of its investigational antisense oligonucleotide (ASO), ISTH0036, in patients with ...

NEW YORK – Sangamo Therapeutics is hoping to submit a biologics license application to the US Food and Drug Administration in 2026 and seek approval to market its gene therapy for Fabry disease, ...